Chronic subdural hematoma management with MMA embolization ± surgery: Pre-existing statin therapy did not reduce

Fee Christiane Keil1, Emma Becke1, Rejane Golbach2

  • 1Goethe University Frankfurt, University Hospital, Institute of Neuroradiology Frankfurt am Main, Germany.

Brain & Spine
|January 14, 2026
PubMed

Insights

Pre-existing statin therapy did not reduce chronic subdural hematoma (CSDH) recurrence after middle meningeal artery embolization (MMAE). Surgery combined with MMAE showed no recurrence, unlike MMAE alone, but further research is needed.

Area of Science:

  • Neurosurgery
  • Interventional Neurology
  • Vascular Neurology

Background:

  • Chronic subdural hematoma (CSH) recurrence is a clinical challenge.
  • Statins are explored for their potential to reduce CSH recurrence rates.
  • Middle meningeal artery embolization (MMAE) is an emerging treatment for CSH.

Purpose of the Study:

  • To investigate whether pre-existing statin therapy influences CSH recurrence after MMAE.
  • To compare recurrence rates between MMAE alone and combined surgical evacuation plus MMAE.

Main Methods:

  • Retrospective analysis of 47 CSH cases treated with MMAE between January 2020 and October 2021.
  • Statin exposure was defined as documented use before MMAE and continued during follow-up.
  • Clinical therapy failure was defined as radiological recurrence with new neurological symptoms.

Main Results:

  • The overall recurrence rate was 6.4% (3/47 cases).
  • Statin use (in 38.3% of patients) was not significantly associated with reduced recurrence.
  • No recurrences were observed in cases treated with combined surgery and MMAE, while MMAE alone had events.

Conclusions:

  • Statin use was not associated with reduced CSH recurrence in this cohort undergoing MMAE.
  • Combined surgical evacuation and MMAE demonstrated a potential benefit by avoiding recurrence.
  • These exploratory findings necessitate prospective studies for confirmation due to the small sample size.
Abstract

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...